Finnish multiple sclerosis patients treated with cladribine tablets: a nationwide registry study

• DOI: 10.1016/j.msard.2022.103755
• Publication Date: 2022-03-20T00:23:44Z
• Authors: Ilkka Rauma; Matias Viitala; Hanna Kuusisto; Sari Atula; Jussi O T Sipilä; Mervi Ryytty; Merja Soilu-Hänninen; Elina Järvinen
• Keywords: Interquartile range; Cladribine

Cladribine tablets for adult patients with highly active relapsing multiple sclerosis (MS) have been available in Finland since 2018. Real-world data from different genetic and geographical backgrounds are needed to complement clinical trials.We investigated the use of cladribine a non-interventional cohort study, based on real-world nationwide Finnish MS registry. All eligible who had initiated treatment 2018-2020 were included. Descriptive analyses outcomes conducted using summary statistics. Time-dependent endpoints analyzed cumulated events analysis 1-Kaplan-Meier estimates curves. Subgroups separately according number previous disease-modifying therapies (DMTs) most common last preceding therapies.Data 179 analyzed. Median follow-up time was 19.0 months (interquartile range [IQR] 12.0-26.2). Of 134 followed at least 12 months, 112 (83.6%) remained relapse-free during follow-up. Mean annualized relapse rate (ARR) 1.0 (standard deviation [SD] 0.89) baseline, 0.1 (SD 0.30) Patients two or more DMTs shorter first (median 2.5 IQR 0.6-9.3) when compared 0-1 11.4 8.7-13.1) (p=0.013). After excluding switching fingolimod (n=33), statistically significant difference no longer observed between groups (p=0.252). Adverse (AEs) reported 30 (16.8%). The frequent AE headache (n=14, 7.8%). One patient (0.6%) died cardiac arrest. Discontinuation nine (5.0%).The mean ARR this similar what has trials. Approximately half used before tablets. These DMTs, mostly driven by early relapses fingolimod.